无数据
Scan for full text
1.Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China
2.Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital and Institute of Translational Medicine, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310029, China
3.Institute of Genetics, Zhejiang University, Hangzhou 310058, China
4.Division of Hematopoietic Stem Cell & Leukemia Research, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA
5.Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
纸质出版日期: 2024-08-15 ,
收稿日期: 2023-08-03 ,
修回日期: 2023-10-15 ,
林黎明,陶菁菁,孟颖等.全基因组CRISPR筛选揭示PTEN基因在急性髓系白血病化疗敏感性中的关键作用[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2024,25(08):700-710.
Liming LIN, Jingjing TAO, Ying MENG, et al. Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (
林黎明,陶菁菁,孟颖等.全基因组CRISPR筛选揭示PTEN基因在急性髓系白血病化疗敏感性中的关键作用[J].浙江大学学报(英文版)(B辑:生物医学和生物技术),2024,25(08):700-710. DOI: 10.1631/jzus.B2300555.
Liming LIN, Jingjing TAO, Ying MENG, et al. Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (
近年来,在急性髓系白血病(AML)治疗的新型靶向药物开发方面虽取得显著进展,但目前化疗仍然是主要的治疗手段,大多数患者的总体生存率仍较低。本研究展示了一种新型小分子化合物NL101的抗白血病活性,该化合物是通过在苯达莫司汀的侧链加上辛二酰苯胺异羟肟酸(SAHA)基团修饰形成。NL101能抑制髓系恶性肿瘤细胞和原发性AML细胞的增殖,并可诱导DNA损伤和半胱天冬酶3介导的细胞凋亡。全基因组CRISPR文库筛选发现,
PTEN
基因在NL101处理后调节细胞存活中起到关键作用。
PTEN
敲除或抑制伴随着AKT信号通路的激活,可显著降低AML和骨髓增生异常综合征(MDS)细胞对NL101诱导的凋亡作用。雷帕霉素联用可通过抑制mTOR增强AML细胞对NL101诱导细胞死亡的敏感性。上述发现揭示了PTEN蛋白的表达是NL101化疗敏感性的主要决定因素,这提供了一种新的治疗策略,为NL101与雷帕霉素联合治疗AML提供了理论依据。
Although significant progress has been made in the development of novel targeted drugs for the treatment of acute myeloid leukemia (AML) in recent years
chemotherapy still remains the mainstay of treatment and the overall survival is poor in most patients. Here
we demonstrated the antileukemia activity of a novel small molecular compound NL101
which is formed through the modification on bendamustine with a suberanilohydroxamic acid (SAHA) radical. NL101 suppresses the proliferation of myeloid malignancy cells and primary AML cells. It induces DNA damage and caspase 3-mediated apoptosis. A genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) library screen revealed
that phosphatase and tensin homologous (
PTEN
) gene is critical for the regulation of cell survival upon NL101 treatment. The knockout or inhibition of
PTEN
significantly reduced NL101-induced apoptosis in AML and myelodysplastic syndrome (MDS) cells
accompanied by the activation of protein kinase B (AKT) signaling pathway. The inhibition of mammalian target of rapamycin (mTOR) by rapamycin enhanced the sensitivity of AML cells to NL101-induced cell death. These findings uncover PTEN protein expression as a major determinant of chemosensitivity to NL101 and provide a novel strategy to treat AML with the combination of NL101 and rapamycin.
CRISPR/Case9全基因组敲除文库PTEN雷帕霉素急性髓系白血病化疗
Genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) libraryPhosphatase and tensin homologous (PTEN)RapamycinAcute myeloid leukemia (AML)Chemotherapy
Burnett AK, das Gupta E, Knapper S, et al., 2018. Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. Haematologica, 103(10):1654-1661. https://doi.org/10.3324/haematol.2018.189514https://doi.org/10.3324/haematol.2018.189514
Calimeri T, Ferreri AJM, 2017. m-TOR inhibitors and their potential role in haematological malignancies. Br J Haematol, 177(5):684-702. https://doi.org/10.1111/bjh.14529https://doi.org/10.1111/bjh.14529
Contieri B, Duarte BKL, Lazarini M, 2020. Updates on DNA methylation modifiers in acute myeloid leukemia. Ann Hematol, 99(4):693-701. https://doi.org/10.1007/s00277-020-03938-2https://doi.org/10.1007/s00277-020-03938-2
del Peso L, González-García M, Page C, et al., 1997. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science, 278(5338):687-689. https://doi.org/10.1126/science.278.5338.687https://doi.org/10.1126/science.278.5338.687
Hou PP, Wu C, Wang YC, et al., 2017. A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220. Cancer Res, 77(16):4402-4413. https://doi.org/10.1158/0008-5472.CAN-16-1627https://doi.org/10.1158/0008-5472.CAN-16-1627
Jiang H, Pritchard JR, Williams RT, et al., 2011. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol, 7(2):92-100. https://doi.org/10.1038/nchembio.503https://doi.org/10.1038/nchembio.503
Kantarjian HM, Kadia TM, DiNardo CD, et al., 2021. Acute myeloid leukemia: treatment and research outlook for 2021 and the MD Anderson approach. Cancer, 127(8):1186-1207. https://doi.org/10.1002/cncr.33477https://doi.org/10.1002/cncr.33477
Kayser S, Levis MJ, 2018. Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol, 180(4):484-500. https://doi.org/10.1111/bjh.15032https://doi.org/10.1111/bjh.15032
Kurata M, Rathe SK, Bailey NJ, et al., 2016. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML. Sci Rep, 6:36199. https://doi.org/10.1038/srep36199https://doi.org/10.1038/srep36199
Lee JH, Liu R, Li J, et al., 2017. Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis. Nat Commun, 8:949. https://doi.org/10.1038/s41467-017-00906-9https://doi.org/10.1038/s41467-017-00906-9
Ley TJ, Miller C, Ding L, et al., 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368(22):2059-2074. https://doi.org/10.1056/NEJMoa1301689https://doi.org/10.1056/NEJMoa1301689
Li S, He X, Gan YC, et al., 2021. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma. Theranostics, 11(7):3439-3451. https://doi.org/10.7150/thno.53561https://doi.org/10.7150/thno.53561
Liu C, Ding HY, Li XX, et al., 2015. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med, 7(4):438-449. https://doi.org/10.15252/emmm.201404580https://doi.org/10.15252/emmm.201404580
Liu YF, Yang EJ, Zhang BY, et al., 2018. PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A. Cancer Lett, 436:28-37. https://doi.org/10.1016/j.canlet.2018.08.011https://doi.org/10.1016/j.canlet.2018.08.011
López-Iglesias AA, Herrero AB, Chesi M, et al., 2017. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. J Hematol Oncol, 10:127. https://doi.org/10.1186/s13045-017-0495-yhttps://doi.org/10.1186/s13045-017-0495-y
Mahalingam D, Medina EC, Esquivel JA, et al., 2010. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res, 16(1):141-153. https://doi.org/10.1158/1078-0432.Ccr-09-1385https://doi.org/10.1158/1078-0432.Ccr-09-1385
Mak LH, Vilar R, Woscholski R, 2010. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol, 3(4):157-163. https://doi.org/10.1007/s12154-010-0041-7https://doi.org/10.1007/s12154-010-0041-7
Morotti A, Panuzzo C, Crivellaro S, et al., 2015. The role of PTEN in myeloid malignancies. Hematol Rep, 7(4):6027. https://doi.org/10.4081/hr.2015.6027https://doi.org/10.4081/hr.2015.6027
Nogueira V, Park Y, Chen CC, et al., 2008. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell, 14(6):458-470. https://doi.org/10.1016/j.ccr.2008.11.003https://doi.org/10.1016/j.ccr.2008.11.003
Ruiz S, Mayor-Ruiz C, Lafarga V, et al., 2016. A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors. Molecular Cell, 62(2):307-313. https://doi.org/10.1016/j.molcel.2016.03.006https://doi.org/10.1016/j.molcel.2016.03.006
Sanjana NE, Shalem O, Zhang F, 2014. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods, 11(8):783-784. https://doi.org/10.1038/nmeth.3047https://doi.org/10.1038/nmeth.3047
Saygin C, Carraway HE, 2017. Emerging therapies for acute myeloid leukemia. J Hematol Oncol, 10:93. https://doi.org/10.1186/s13045-017-0463-6https://doi.org/10.1186/s13045-017-0463-6
Shalem O, Sanjana NE, Hartenian E, et al., 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343(6166):84-87. https://doi.org/10.1126/science.1247005https://doi.org/10.1126/science.1247005
Shao F, Gao YB, Wang W, et al., 2022. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. Nat Cancer, 3(10):1192-1210. https://doi.org/10.1038/s43018-022-00444-4https://doi.org/10.1038/s43018-022-00444-4
Steube KG, Gignac SM, Hu ZB, et al., 1997. In vitro culture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1. Leuk Lymphoma, 25(3-4):345-363. https://doi.org/10.3109/10428199709114174https://doi.org/10.3109/10428199709114174
Teachey DT, Grupp SA, Brown VI, 2009. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol, 145(5):569-580. https://doi.org/10.1111/j.1365-2141.2009.07657.xhttps://doi.org/10.1111/j.1365-2141.2009.07657.x
Yamaguchi H, Wang HG, 2001. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene, 20(53):7779-7786. https://doi.org/10.1038/sj.onc.1204984https://doi.org/10.1038/sj.onc.1204984
Zheng L, Liang H, Zhang QL, et al., 2022. circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF-β/Smad signaling. Mol Cancer, 21:41. https://doi.org/10.1186/s12943-022-01495-yhttps://doi.org/10.1186/s12943-022-01495-y
Zheng YH, Yang WW, Xia Y, et al., 2011. Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol, 31(21):4258-4269. https://doi.org/10.1128/Mcb.05547-11https://doi.org/10.1128/Mcb.05547-11
Zheng YH, Yang WW, Aldape K, et al., 2013. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. J Biol Chem, 288(44):31488-31495. https://doi.org/10.1074/jbc.M113.499020https://doi.org/10.1074/jbc.M113.499020
0
浏览量
17
Downloads
0
CSCD
关联资源
相关文章
相关作者
相关机构